This workshop seeks to recognize various general designs and analyses related to the issue of false positive findings, understanding the statistical methodology in the design and the implementation of interim analyses, and other statistics challenges that
BEIJING, CHINA (PRWEB) October 22, 2012
DIA, the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide will host the 2012 Statistical Workshop, two days focusing on understanding the statistical thinking in clinical research for drug development and control overall false positive rate in clinical trials to ensure the validity of trial results. This workshop will be held in Beijing, October 26 and 27 at the Beijing Jade Palace Hotel.
This year’s workshop also allows college students and graduates who have an interest in drug development and clinical statistics to attend this special DIA event.
Special subjects include control of overall false positive rate, concept and methodology for multiple comparisons, issues of multiple endpoints, interim analysis, Group Sequential Design (GSD) and statistical analysis, sample size re-estimation and real life clinical trial examples.
- The workshop will open with the Chairperson’s Opening remarks, with speaker Professor Chen Yao, Associate Director, Peking University Clinical Research Institute, China, kicking off session 1.
- Session 2 speaker Robert Luo, PhD, Director, Clinical Statistics, Pfizer (China) Research and Development Co Ltd, China will present on Multiple Comparisons.
- Weiying Yuan, PhD, Site Head of Biostatistics & Programming, Johnson & Johnson PRD, China, will present Session 3 topic, Multiple Endpoints.
- Session 4, Case Studies, will be presented by speaker Robert Luo and Weiying Yuan.
- Session 5: Interim Analysis (IA), Group Sequential Methods (GSMs), and Type I Error Rate Spending Approach (Part 1), will be presented by Irving Keou Hwang, PhD, President, Irving Consulting Group, United States.
- Session 6: Sample Size Re-estimation, will be presented by speaker William Wang, PhD, Head of Asia Pacific Hub, Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories, Merck & Co., Inc., China.
- Session 7, Interim Analysis (IA), Group Sequential Methods (GSMs) (Part 2)-Case Studies will be presented by speaker Irving Keou Hwang.
The second day of sessions will be followed by a Panel Discussion and the Chairperson’s closing remarks.
“This workshop seeks to recognize various general designs and analyses related to the issue of false positive findings, understanding the statistical methodology in the design and the implementation of interim analyses, and other statistics challenges that those in clinical sciences face,” explains program co-chairperson Roger QU, PhD, Head of Clinical Statistics Pfizer (China) Research and Development Center, China.
Don’t miss out on this highly anticipated workshop.
For general inquiries and registration, contact:
Mr. Fei XIE
fei.xie(at)diachina(dot)org or dia(at)diachina(dot)org
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. http://www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, and YouTube. Stay updated on hot topic news at #druginfoassn on Twitter.